Preclinical studies have highlighted the promising role of maraviroc in anti-tumor therapies through the CCL5/CCR5 pathway, including breast cancer, colon cancer, glioblastoma, and gastric cancer [56–60]. This evidence concerns the gene CCR5 and glioblastoma.